Integrative Analysis of Identifying Methylation-Driven Genes Signature Predicts Prognosis in Colorectal Carcinoma

Hao Huang1, Jinming Fu1, Lei Zhang1, Jing Xu1, Dapeng Li1, Justina Ucheojor Onwuka1, Ding Zhang1, Liyuan Zhao1, Simin Sun1, Lin Zhu1, Ting Zheng1, Chenyang Jia1, Binbin Cui2* and Yashuang Zhao1*

1 Department of Epidemiology, Public Health School of Harbin Medical University, Harbin, China, 2 Department of Colorectal Surgery, The Third Hospital of Harbin Medical University, Harbin, China

**Background:** Aberrant DNA methylation is a critical regulator of gene expression and plays a crucial role in the occurrence, progression, and prognosis of colorectal cancer (CRC). We aimed to identify methylation-driven genes by integrative epigenetic and transcriptomic analysis to predict the prognosis of CRC patients.

**Methods:** Methylation-driven genes were selected for CRC using a MethylMix algorithm and LASSO regression screening strategy, and were further used to construct a prognostic risk-assessment model. The Cancer Genome Atlas (TCGA) database was obtained as the training set for both the screening of methylation-driven genes and the effect of genes signature on CRC prognosis. Then, the prognostic genes signature was validated in three independent expression arrays of CRC data from Gene Expression Omnibus (GEO).

**Results:** We identified 143 methylation-driven genes, of which the combination of BATF, PHYHIPL, RBP1, and PNPLA4 expression levels was screened as a better prognostic model with the best area under the curve (AUC) (AUC = 0.876). Compared with patients in the low-risk group, CRC patients in the high-risk group had significantly poorer overall survival in the training set (HR = 2.184, 95% CI: 1.404–3.396, P < 0.001). Similar results were observed in the validation set. Moreover, VanderWeele’s mediation analysis indicated that the effect of methylation on prognosis was mediated by the levels of their expression (HRindirect = 1.473, P = 0.001, Proportion mediated, 69.10%).

**Conclusions:** We identified a four-gene prognostic signature by integrative analysis and developed a risk-assessment model that is significantly associated with patients’ survival. Methylation-driven genes might be a potential prognostic signature for CRC patients.

**Keywords:** colorectal cancer, methylation-driven genes, prognostic risk model, integrative analysis, overall survival
INTRODUCTION

Colorectal cancer (CRC) is the most common malignant tumor of the digestive system (1). Although recent advances in diagnostic and therapeutic modalities for CRC have greatly improved in survival with early colorectal carcinoma, the 5-year overall survival (OS) rates remain low in the late stage of CRC (2, 3). According to the SEER database (1973–2014, 2017 release), the 5-year survival rate for stage IV patients with metastases is only 11% (4). Nowadays the tumor-node-metastasis (TNM) staging system is identified as the gold standard to determine the prognosis of CRC patients. However, the effects and prognosis of CRC patients in the same stage using the same treatment are very different, demonstrating that there is the heterogeneity of tumor prognosis in the same stage and thus, the traditional TNM staging system fails to reflect tumor heterogeneity and assess the prognosis of CRC patients accurately (5, 6). Therefore, more effective prognostic biomarkers are needed to evaluate CRC prognosis.

DNA methylation is one of the most frequently occurring epigenetic modifications, which plays a crucial role in regulating gene expression and genome function (7). A series of studies have reported significant biomarkers for predicting the prognosis of CRC patients at different omics levels, including DNA methylation (8), microRNAs (9), gene expression (10), and proteins (11). These studies are based on single-level OMICS to consider the complicated process of tumor development (12). While the multi-OMICS may understand the biological behavior of tumors more systematically in multiple dimensions to further reveal complex molecular mechanisms in different phenotypic manifestations and discover molecular candidates with prognostic values (13). Recent studies have a trend of integrating omics to better screen potential prognostic biomarkers (14, 15). Currently, there is a driven regulation mode for selective recognition of hypermethylated or hypomethylated genes that can regulate gene expression and form specific tissue types during development (16). This mode may identify methylation-driven genes, which serve as a key indicator in the development, progression, and prognosis of tumors. At present, studies on methylation-driven genes to evaluate the prognosis of patients have been reported in the bladder (17), hepatocellular (18), and gastric cancers (19). Therefore, it is imperative to combine the profiles of DNA methylation and expression to identify CRC-related methylation-driven genes and evaluate the prognosis of CRC patients.

Here, CRC-related specific methylation-driven genes were based on the MethylMix algorithm. These genes were selected by the profiles of genome-wide DNA methylation and gene expression from The Cancer Genome Atlas (TCGA) and were validated from ArrayExpress databases. We further constructed a prognostic model to predict the overall survival (OS) of CRC patients in TCGA datasets and validated this model by Gene Expression Omnibus (GEO) datasets. The time-dependent receiver operating characteristic (ROC) curves and nomograms were utilized to estimate the capability of prediction for the prognostic model in two datasets.

MATERIALS AND METHODS

Study Population and Data Preprocessing

All the subjects used in this study were obtained from publicly available databases, including TCGA, GEO, and ArrayExpress databases. Methylation-driven genes for CRC were identified by the profiles of DNA methylation and gene expression from TCGA (N = 431), including 386 CRC tissues and corresponding 45 adjacent non-tumor tissue samples. Then these candidate genes were validated further from ArrayExpress databases (N = 214) where contain 214 CRC tissue samples. A prognostic risk-assessment model was developed based on TCGA datasets (N = 367) and was validated the model by Gene Expression Omnibus (GEO) datasets (N = 355) of three-independent gene expression arrays [GSE17536 (N = 177), GSE17537 (N = 55), and GSE72970 (N = 123)], where the CRC clinical information included sex, age, TNM stage, and survival.

Level 3 methylation data were obtained from the TCGA Methylation 450k Bead chip by the function of the DownloadMethylationData in a TCGA-Assembler 2 Bioconductor package (18, 20). According to the function of the CalculateSingleValueMethylationData, the average value of all CpG sites in the promoter region between the transcription start site (TSS) 200 and TSS 1,500 bps was calculated. Meanwhile, RNA-seq expression data were also collected from TCGA database. The RNA-Seq data were normalized by function ProcessRNASeqData.

Identification and Validation of Methylation-Driven Genes for CRC

MethylMix is an R package using the analysis of the correlation between methylation level and gene expression level (21). According to the Bioconductor package MethylMix, we integrated DNA methylation data of the tumor tissue samples and normal tissue samples, and gene expression data of CRC tissue samples in TCGA datasets to screen most likely specific driven genes for CRC. The highly correlated genes were selected for further analyses. We compared the DNA methylation status in tumor versus normal patients by Wilcoxon rank-sum test. Absolute log fold change (FC) ≥0, correlation coefficient (Cor) < −0.5 and adjusted P < 0.05 were used as screening conditions. Finally, we screened out 143 methylation-driven genes for further analyses according to the requirements of the MethylMix algorithm. To further narrow the predictors, a least absolute shrinkage and selection operator (LASSO) regression was used to narrow the range of methylation-driven genes. A
strong correlation often exists between the variables, indicating that high dimensionality and collinearity. And this LASSO model method could decrease the characteristic dimension. Then, a multivariable Cox regression model to select driven genes that were most closely associated with survival was constructed and six methylation-driven genes were retained (22, 23).

Moreover, a total of 214 CRC patients contained both DNA methylation and expression data were collected from patients for surgery at the Royal Brisbane and Women’s Hospital in Brisbane, Australia, a consecutive manner between 2009 and 2012 (24). We analyzed these six methylation-driven genes whose correlation between the methylation levels of promoter probes and those gene expressions to further validate whether are the candidate methylation-driven genes. The correlation between methylation level in the promoter region and their corresponding gene expression level was calculated by Pearson’s rank. The data have been stored at EMBL-EBI (https://www.ebi.ac.uk/arrayexpress/) from the ArrayExpress database. The accession numbers are E-MTAB-7036 (methylation) and E-MTAB-8148 (expression).

Construction and Validation of a Prognostic Risk-Assessment Model
To better assess the prognostic predictive power of those methylation-driven genes, we construct a prognostic risk-score model by multivariable Cox analysis:

\[
Risk\ \text{score (RS)} = \sum_{i=1}^{N} (\text{Exp} \times \text{Coef}),
\]

In which, \(N\) represents the number of methylation-driven genes; \(\text{Exp}\) is the expression level of every driven gene, and \(\text{Coef}\) is the coefficient of multivariable Cox regression analysis in the model. Risk score (RS) is a multimode weighted sum of the prognostic risk value of each sample. Six methylation-driven genes could combine \(2^{6} - 1 = 63\) signatures, therefore, every CRC patient has 63 prognostic risk scores. In the training set, the hazard ratios (HR) and the area under curves (AUCs) values from the prognostic score of the 63 signatures were analyzed. We constructed the best prognostic risk model by comparing each AUC value in 63 signatures.

To validate the predictive capability of the best risk-assessment model, we obtained three gene expression arrays of human CRC datasets [GSE17536 (N = 177), GSE17537 (N = 55), and GSE72970 (N = 123)] from the Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/), serving as a validation cohort (N = 355) (25–27). To minimize batch effects from different microarray platforms, samples in three different datasets were selected from the same chip platform (Affymetrix Human Genome U133 Plus 2.0 Array) and normalized with by Bioconductor package Sva (28, 29).

Gene Set Enrichment Analysis (GSEA)
To explore the potential biological function and promising signaling pathways correlated with the methylation of driven genes, GSEA was conducted to analyze the biological function of four genes using the Java GSEA v4.0.1 software (http://software.broadinstitute.org/gsea/datasets.jsp). The files of ontology gene sets were collected from the Gene Ontology (GO) (c5.all.v7.1.symbols) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) (c2.cp.kegg.v7.1.symbols) databases. The screening conditions of significant pathways and biological functions were the absolute value of normalized enrichment score (NES) >1, P-value <0.05, and false discovery rate (FDR) q value <0.05.

Statistical Analysis
The median cut-off value divided CRC patients into high-risk and low-risk groups. The analysis of time-dependent ROC curves and Kaplan-Meier survival analysis were utilized to compare the survival rates at different follow-up time points and the difference of the OS between the two groups for CRC patients. Then, univariable and multivariable Cox regression analyses were performed to illustrate whether the methylation signature model is serving as an independent indicator. Before conducting multivariable Cox regression models, we successfully estimated the assumption by the equal-proportional hazards assumption. Moreover, in order to evaluate further the survival probability of individual patient’s outcome events, the clinical factors (age, gender, and TNM staging) and risk score of genes signature were used to build the nomogram by utilizing the rms and the Hmisc packages in R. In the nomogram, each patient had a score for predicting each survival probability, and a higher number of total points represented a worse outcome for the patient. Calibration curves were calculated to estimate the efficiency of the nomogram. VanderWeele’s mediation analysis was utilized to explore whether the effect of the methylation signature on prognosis is affected by their mRNA expression (30). The total effect of methylation on prognosis (HR\text{Total}) was split into two effects, including the direct effect (HR\text{Direct}) which represents the direct effect of the methylation on prognosis, and the indirect effect (HR\text{Indirect}) that indicates the prognostic effect of methylation mediated through gene expression. All analyses were performed with the R Statistical Program (version 3.6.1). P-value <0.05 were considered statistically significant.

RESULTS
Clinical Characteristics of the Patients
The clinical information of CRC patients contained a training cohort (N = 367) that was extracted from the TCGA database and a validation cohort (N = 355) that was obtained from GEO datasets (GSE17536, GSE17537, and GSE72970). The patients’ characteristics are summarized in Table 1.

Identification and Validation of CRC Methylation–Driven Genes
By the MethylMix algorithm, we identified 143 methylation-driven genes that were transcriptionally regulated with methylation status. The process of determining and analyzing methylation-driven genes signature is displayed in Supplementary Figure S1. These
genes are summarized in Figure 1A and Supplementary Table S1. After screening out these 143 methylation-driven genes, we included these genes in the LASSO model. We found that when the λ value is 0.038, the cross-validation error coefficient of the model is lowest, and the corresponding genes are ten (ANXA9, BATF, PHYHIPL, RBP1, PNPLA4, FCGBP, GIPC2, FGC2, FAM131A, and SERPINA1) (Figures 1B, C). Then, 10 genes included these genes in the LASSO model. We found that when the cross-validation error coefficient of the model is lowest, and the corresponding genes are ten (ANXA9, BATF, PHYHIPL, RBP1, PNPLA4, FCGBP, GIPC2, FGC2, FAM131A, and SERPINA1) (Figures 1B, C). Then, 10 genes obtained by the LASSO regression model were incorporated into the multivariable Cox model. And finally obtained six methylation-driven genes (ANXA9, BATF, PHYHIPL, RBP1, PNPLA4, and SERPINA1) (Supplementary Table S2). We further validated the correlation between methylation level of probes in the promoter region and corresponding gene expression level in a total of 214 patients from the ArrayExpress database. Due to the partially missing in the methylation 450K bead chip data, we validated only four methylation-driven genes (ANXA9, BATF, RBP1, and SERPINA1). However, the stable results of candidate genes were similar to training sets (Supplementary Figure S2).

Construction and Validation of the Prognostic Risk-Assessment Model in the Training and Testing Sets

According to the risk score of the prognostic model in the training set, these six methylation-driven genes have $2^6 - 1 = 63$ possible combinations and relevant prognostic risk scores. By calculating AUC values of 63 signatures, we found that the expression signature consisted of BATF, PHYHIPL, PNPLA4, and RBP1 was served as a better prognostic signature (Supplementary Table S3). The prognostic risk score of these combined four genes was determined as follows: Risk score = (0.253 × expression level of BATF) + (0.147 × expression level of PHYHIPL) + (−0.183 × expression level of PNPLA4) + (−0.172 × expression level of RBP1) (Table 2). The AUC value of four methylation-driven genes signature was 0.876, demonstrating a better capability of prediction with the 9-year OS of CRC patients. The Kaplan-Meier survival analysis demonstrated that CRC patients in the high-risk group had poorer survival than those in the low-risk group (HR = 2.184, 95% CI: 1.404–3.396, $P < 0.001$) (Figure 2). Moreover, we further analyzed the difference of expression levels of four genes in tumor and normal tissues and found that the expression level of PHYHIPL (P = 0.002) in CRC tissues is lower than that of normal tissue. While the expression level of BATF in normal tissue is lower than that of CRC tissue (P = 0.002). However, the expression levels of PNPLA4 and RBP1 are not significantly different between CRC tissue and normal tissue (Supplementary Figure S3).

To validate the predictive capability of the expression prognostic genes signature, the same prognostic model was used to calculate the risk scores of a total of 355 CRC patients in the independent testing set of the GEO database. The Kaplan-Meier survival analysis showed CRC patients in the high-risk group had significantly poorer survival than those in the low-risk group (HR = 1.963, 95% CI: 1.456–2.647, $P < 0.001$) (Supplementary Figure S4). These results were similar to those in the training set.

Furthermore, we built the mediation model underlying the mediation pathway of methylation, mRNA expression, and OS by VanderWeele’s mediation analysis (Figure 3A). The effect of the methylation signature of combined four genes on prognosis was mostly mediated by their corresponding mRNA expression (HRindirect = 1.473, 95% CI: 1.165–1.862, $P = 0.001$, Proportion mediated, 69.10%). After excluding the methylation and expression of each gene, the result of sensitivity analysis retained statistically significant in the indirect effect (Figure 3B).

Assessment of the Predictive Performance of the Expression Prognostic Model by Time-Dependent ROC Curves and the Nomogram

According to a time-dependent ROC curves analysis, in the training set, we observed that their AUC values were 0.626 at 3 years, 0.670 at 5 years, and 0.885 at 10 years, respectively.

---

**TABLE 1 | Summary of patient demographics and clinical characteristics.**

| Characteristics | Groups | Total (N = 722) | Training set (N = 367) | Testing set (N = 355) |
|-----------------|--------|----------------|------------------------|-----------------------|
|                 | No.    | %              | No.                    | %                      | No.                    | %                      |
| Age at diagnosis| Median | 65.3           | 64.4                   | 63.7                   |
|                 | Range  | 21.0–97.0      | 31.0–90.0              | 21.0–94.0              |
|                 | <65 years | 354           | 172              | 182                    |
|                 | ≥65 years | 368           | 195              | 173                    |
| Gender          | Male   | 394            | 199            | 195                    |
|                 | Female | 328            | 168            | 160                    |
| TNM stage       | I      | 86             | 55             | 31                     |
|                 | II     | 216            | 141            | 75                     |
|                 | III    | 208            | 117            | 91                     |
|                 | IV     | 212            | 54             | 158                    |
| Vital status    | Living | 458            | 287            | 171                    |
|                 | Dead   | 264            | 80             | 184                    |

---

**Construction and Validation of the Prognostic Risk-Assessment Model in the Training and Testing Sets**

According to the risk score of the prognostic model in the training set, these six methylation-driven genes have $2^6 - 1 = 63$ possible combinations and relevant prognostic risk scores. By calculating AUC values of 63 signatures, we found that the expression signature consisted of BATF, PHYHIPL, PNPLA4, and RBP1 was served as a better prognostic signature (Supplementary Table S3). The prognostic risk score of these combined four genes was determined as follows: Risk score = (0.253 × expression level of BATF) + (0.147 × expression level of PHYHIPL) + (−0.183 × expression level of PNPLA4) + (−0.172 × expression level of RBP1) (Table 2). The AUC value of four methylation-driven genes signature was 0.876, demonstrating a better capability of prediction with the 9-year OS of CRC patients. The Kaplan-Meier survival analysis demonstrated that CRC patients in the high-risk group had poorer survival than those in the low-risk group (HR = 2.184, 95% CI: 1.404–3.396, $P < 0.001$) (Figure 2). Moreover, we further analyzed the difference of expression levels of four genes in tumor and normal tissues and found that the expression level of PHYHIPL (P = 0.002) in CRC tissues is lower than that of normal tissue. While the expression level of BATF in normal tissue is lower than that of CRC tissue (P = 0.002). However, the expression levels of PNPLA4 and RBP1 are not significantly different between CRC tissue and normal tissue (Supplementary Figure S3).

To validate the predictive capability of the expression prognostic genes signature, the same prognostic model was used to calculate the risk scores of a total of 355 CRC patients in the independent testing set of the GEO database. The Kaplan-Meier survival analysis showed CRC patients in the high-risk group had significantly poorer survival than those in the low-risk group (HR = 1.963, 95% CI: 1.456–2.647, $P < 0.001$) (Supplementary Figure S4). These results were similar to those in the training set.

Furthermore, we built the mediation model underlying the mediation pathway of methylation, mRNA expression, and OS by VanderWeele’s mediation analysis (Figure 3A). The effect of the methylation signature of combined four genes on prognosis was mostly mediated by their corresponding mRNA expression (HRindirect = 1.473, 95% CI: 1.165–1.862, $P = 0.001$, Proportion mediated, 69.10%). After excluding the methylation and expression of each gene, the result of sensitivity analysis retained statistically significant in the indirect effect (Figure 3B).

**Assessment of the Predictive Performance of the Expression Prognostic Model by Time-Dependent ROC Curves and the Nomogram**

According to a time-dependent ROC curves analysis, in the training set, we observed that their AUC values were 0.626 at 3 years, 0.670 at 5 years, and 0.885 at 10 years, respectively.
We further observed AUC values in the testing set, with 3-, 5-, and 8-year were 0.695, 0.716, and 0.803, respectively (Figure 4B). Then, we investigated whether the risk score of genes signature was used as an independent indicator for CRC patients by univariable and multivariable Cox analyses, and found that the prognostic score was an independent prognostic factor in the training set (high-risk group vs low-risk group, HR = 2.221, 95% CI: 1.382–3.571, \( P = 0.001 \)). However, the result in the testing set was a little bit low (high-risk group vs low-risk group, HR = 1.436, 95% CI: 1.051–1.962, \( P = 0.023 \) (Table 3)).

We further built a nomogram, including the risk score of signature and clinical factors (age, gender, and TNM stage). The nomogram served as an individual’s prognostic predictor to predict the probability of overall survival with 1-, 5-, and 10-year for CRC patients (Figure 4C). Moreover, in the training set, calibration plots demonstrated that the nomogram had similar predictive performance compared with an ideal model in predicting the 5-year OS for CRC patients (Figure 4D). Similar results were observed in the testing set (Figures 4E, F) (Concordance-index: 0.747 in the training set and 0.707 in the testing set). Additionally, compared with the TNM staging system, the nomogram had a higher C-index in predicting the OS for CRC patients in the training and testing sets (Supplementary Table S4).

Subgroup Analyses of the Prognostic Performance of the Methylation-Driven Genes Signature
To determine whether our model was highly applicable and precisely predict the OS of CRC patients, we performed
subgroup analyses based on different clinical characteristics (age, gender, and TNM stage). The prognostic effect of the genes signature in different age groups, female groups, TNM stage groups revealed that CRC patients in the high-risk group had significantly poorer survival than those in the low-risk group ($P < 0.001$). However, in the male, similar results could not be observed in the training set (Supplementary Figure S5). Similar results were also observed in the testing set (Supplementary Figure S6).

**Comparison of Prognostic Risk Model With Other Prognostic Biomarkers in CRC**

The ROC curves analysis for other prognostic biomarkers was analyzed just as our expression prognostic risk model, the results indicated that the AUC value of our four-gene signature was better than that of other known prognostic biomarkers (AUC = 0.794). The AUC values of these biomarkers are summarized in Supplementary Figure S7 and Supplementary Table S5. These results revealed that our genes signature had better predictive performance in predicting the long-term OS of CRC patients.

**Functional Enrichment Analysis of Four Methylation-Driven Genes**

We further explored the biological functions of the four genes by GSEA 4.0.1 software and found that the expression level of $BATF$ may be related to the “regulation of viral process” and “non-small cell lung cancer.” The expression level of $PHYHIPL$ may be related to the function of “blastocyst growth” and “WNT signaling pathway.” However, the FDR value is more than 0.25, there may be false-positive results. Moreover, we found that the expression level of $PNPLA4$ may be related to the function of “peroxisome” in both GO and KEGG functional enrichment. The expression level of $RBP1$ may be related to the “morphogenesis of a polarized epithelium” and the “WNT...
signal pathway." However, the FDR value is 1.000, there may be false-positive results (Supplementary Figure S8).

**DISCUSSION**

Because CRC patients with the same pathological staging often differ in survival, a new prognostic assessment model is required to indicate biological heterogeneity, appropriately guide clinical assessment and intervention, and individualize treatment (6). Previous studies have indicated that DNA methylation, an epigenetic modification, regulates gene expression in the development and progression of cancer (31). Moreover, the comprehensive analysis of DNA methylation and gene expression data can better analyze the regulatory function of methylation and effectively predict the prognosis of tumor patients (32). Therefore, methylation-driven genes may be identified as potential prognostic biomarkers with involvement in pathogenesis (17, 33). Besides, the development and progression of tumors involve the process of a complex regulatory network. Compared with a single biomarker, integrating multiple biomarkers into a combined model could better assess the prognostic value (34). We construct a prognostic model based on four methylation-driven genes and provide a comprehensive prospect for both basic research and clinical applications of methylation-driven genes.

In this study, we used different statistical analyses and the LASSO penalized model obtaining 143 methylation-driven genes. Four out of them (BATF, PHYHIPL, PNPLA4, and RBP1) were identified as genes associated with CRC prognosis, which were selected to develop a prognostic score model and validated the model in external testing set. The results showed that the prognostic score was significantly associated with the OS of CRC patients, demonstrating that CRC patients in the high-risk group have significantly poorer survival than those in the low-risk group. The AUC value based on genes signature was 0.874 in predicting the 9-year of OS for CRC patients in the training set. We further revealed that the risk score of prognostic signature could serve as an independent indicator of patient survival without the effect of age, gender, and TNM stage.

Besides, the nomogram was generated to predict the survival probability of individual patients’ models, thus evaluating the probability of outcome events. The calibration plots indicated that the predicted survival was close to the actual survival status.
These results revealed the obvious predictive capability of genes signature on the prognosis of CRC patients. Moreover, in the stratified analysis, our prognostic model performed well stability for predicting the survival of CRC patients in different age, female, and TNM stage groups in the training and testing sets. However, the males’ group in the training set could not distinguish between low- and high-risk groups. Since this is the first study of methylation-driven genes for CRC, large sample sizes may be necessary to further analyze in the future. Additionally, a comparison of our prognostic signature with other prognostic biomarkers revealed that it had a higher predictive performance with OS of CRC patients.

After a series of analyses, our study provides four prognostic genes. Among these genes, three (BATF, PHYHIPL, and RBPI) have been reported as cancer-associated genes. BATF, a transcription factor, belongs to a highly conserved member of activator protein 1 (AP-1) and a family of the basic leucine zipper ATF-like transcription factor (BATF) (35). A series of studies suggest that BATF may influence the development of different types of cancer, including non-small cell lung cancer (NSCLC), lymphoma, and multiple myeloma (36, 37). Such as, BATF might active NSCLC cell proliferation and apoptosis in BATF-silenced A549 cells (38). In addition, BATF is a gene that inhibits T cell function, inhibitory receptors can cause T cell exhaustion by

---

**FIGURE 4** Predictive OS performance of the signature using time-dependent ROC analysis and the nomogram in training and validation sets. (A) Time-dependent ROC curves analysis for the 3-, 5-, and 10-year OS prediction by signature in the training set. (B) Time-dependent ROC curves analysis for the 3-, 5-, and 8-year OS prediction by signature in the testing set. (C) Nomogram to predict the 1-, 5-, and 10-year OS of CRC patients in the training set. (D) Calibration curves of 5-year OS nomogram model in the training set. (E) Nomogram to predict the 1-, 3-, and 5-year OS of CRC patients in the testing set. (F) Calibration curves of 5-year OS nomogram model in the testing set. The gray line represents the ideal predictive model, and the red line represents the observed model.
PHYHIPL reported that the downregulation of and cervical cancer. Recent studies suggest that RBP1 poor prognosis in various cancer. For example, in EBV-associated hypermethylation and low expression level are associated with a RBP1 region, correlated with the upregulation of proliferation and differentiation of epithelial cells. Recent studies have found that the expression of RBP1 has been reported in many tumor cells, including breast carcinoma, lung adenocarcinoma, tongue squamous cell carcinoma, and cervical cancer. Recent studies suggest that RBP1 hypermethylation and low expression level are associated with a poor prognosis in various cancer. For example, in EBV-associated gastric carcinoma, hypermethylation of RBP1 in the promoter region, correlated with the upregulation of RBP1, which demonstrated that patients with CpG island methylator phenotype-high (CIMP-H) have poorer survival than those with CIMP-low in gastric carcinoma. PNPLA4 (Patatin Like Phospholipase Domain Containing 4) belongs to a member of the patatin-like family of phospholipases, which may be involved in adipocyte triglyceride homeostasis of HeLa cells. Although the function of this gene is still not well known, we observed a significant negative correlation between methylation and expression level of PNPLA4. Therefore, PNPLA4 may indicate a novel CRC biomarker, and further experiments are required to validate this finding.

To the best of our knowledge, this is the first predictive risk model of CRC based on methylation-driven genes. These four genes have not been previously reported on the underlying mechanism of them and studied as a prognostic biomarker in CRC patients. Our study provides a foundation for further exploration into the functions of the four genes. Other strengths include that, compared with previous studies based on methylation-driven genes in other cancers, our study firstly utilized different testing sets to separately validate methylation-driven genes and prognostic models from multi-public datasets. Additionally, we acknowledge several possible limitations to the present study. Firstly, the development and evaluation of this prognostic model were based on publicly available datasets. To further confirm this model, large sample sizes, multicenter, and prospective clinical cohorts may be necessary for the future. Secondly, studies are needed to further verify the biological mechanisms behind the values of these genes for CRC. Regardless, our results showed a significantly consistent association of the signature with OS in different datasets, demonstrating that it serves as a potential prognostic biomarker for CRC.

In summary, we identified 143 methylation-driven genes by integrative analysis of both methylation and expression profiles and selected four of them (BATF, PHYHIPL, RBP1, and PNPLA4) to construct a prognostic risk model. This study reveals that a four-gene methylation-driven prognostic signature accurately predicts the OS of CRC patients and could be a promising marker for improving the clinical prognostic evaluation of CRC patients. DNA methylation-driven genes may be a potentially useful novel biomarker for predicting CRC prognosis.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

HH and JF performed research and drafted the manuscript. LZhang, JX, and DL collected the data, analyzed the data. TZ, CJ, HH and JF performed research and drafted the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We are indebted to all the patients who participated in studies in TCGA and GEO databases for their data assistance during the preparation of this manuscript, and patients from the Royal Brisbane and Women’s Hospital in Brisbane, Australia.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA: Cancer J Clin (2018) 68(1):7–30. doi: 10.3322/caac.21442
2. Rikenomen-Sinisol L, Arnio M, Mecklin JP, Jarvinen HJ. Surveillance Improves Survival of Colorectal Cancer in Patients With Hereditary Nonpolyposis Colorectal Cancer. Cancer Detect Prev (2000) 24(2):137–42.
3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal Cancer Statistics, 2017. CA: Cancer J Clin (2017) 67(3):177–93. doi: 10.3322/caac.21395
4. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (Seer) Program and Pathology: Toward Strengthening the Critical Relationship. Am J Surg Pathol (2016) 40(12):e91–e102. doi: 10.1097/PAS.0000000000000749
5. Benson AB3rd, Venook AP, Cederquist I, Chan E, Chen YJ, Cooper HS, et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 15(3):370–98. doi: 10.6004/jnccn.2017.0036
6. Joung JG, Oh BY, Hong HK, Al-Khalidi H, Al-Alem F, Lee HO, et al. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. Clin Cancer Res (2017) 23(23):7209–16. doi: 10.1158/1078-0432.CCR-17-0306
7. Dor Y, Cedar H. Principles of DNA Methylation and Their Implications for Biology and Medicine. Lancet (London England) (2018) 392(10149):777–86. doi: 10.1016/S0140-6736(18)32168-6
8. Semaan A, Uhl B, Branchi V, Lingohr P, Bootz F, Kristiansen G, et al. Significance of Intron DNA Methylation in Cancer. Cell Oncol (Dordrecht) (2018) 40(12):2992–3022. doi: 10.3322/jcp.2018.00798
9. Liu J, Ke F, Chen T, Zhou Q, Weng L, Tan J, et al. Micronas That Regulate PTEN as Potential Biomarkers in Colorectal Cancer: A Systematic Review. J Cancer Res Clin Oncol (2020) 146(4):809–20. doi: 10.1007/s00432-020-03172-3
10. Yong L, YuFeng Z, Guang B. Association Between Ppp2ca Expression and Colorectal Cancer Prognosis Tumor Marker Prognostic Study. Int J Surg (London England) (2018) 59:80–9. doi: 10.1016/j.ijsu.2018.09.020
11. Taskoparan B, Seza EG, Demirkol S, Tuncer S, Gure AO, et al. Opposing Roles of the Aldo-Keto Reductases Akr1b1 and Akr1b10 in Colorectal Cancer. Cell Oncol (Dordrecht) (2017) 40(6):565–78. doi: 10.1007/s13402-017-0351-7
12. Rappoport N, Shamir R. Multi-Omic and Multi-View Clustering Algorithms: A New Frontier in Cancer Research. Pac Symp Biocomput (2018) 24:1:1–12. doi: 10.1093/bioinformatics/bty304
13. Chakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. BioMed Res Int (2018) 2018:836256. doi: 10.1155/2018/836256
14. Zhao N, Guo M, Wang K, Zhang C, Liu X. Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data. Front Bioeng Biotechnol (2020) 8:268. doi: 10.3389/fbioe.2020.00268
15. Yuan Y, Van Allen EM, Omeroglu L, Wagle N, Amin-Mansour A, Sokolov A, et al. Assessing the Clinical Utility of Cancer Genomic and Proteomic Data Across Tumor Types. Nat Biotechnol (2014) 32(7):644–52. doi: 10.1038/nbt.2940
16. Sandoval J, Esteller M. Cancer Epigenomics: Beyond Genomics. Curr Opin Genet Dev (2012) 22(1):50–5. doi: 10.1016/j.gde.2012.02.008
17. Wang L, Shi J, Huang Y, Liu S, Zhang J, Ding H, et al. A Six-Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients. Cancer Cell Int (2019) 19:229. doi: 10.1186/s12935-019-0950-7
18. Li GX, Ding ZY, Wang YW, Liu TT, Chen WX, WJ, et al. Integrative Analysis of DNA Methylation and Gene Expression Identify a Six Epigenetic Driver Signature for Predicting Prognosis in Hepatocellular Carcinoma. J Cell Physiol (2019) 234(7):11942–50. doi: 10.1002/jcp.27882
19. Bai Y, Wei C, Zhong Y, Zhang Y, Long J, Huang S, et al. Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. Int J Biol Sci (2020) 16(7):1153–65. doi: 10.7150/ijbs.41587
20. Wei L, Jin Z, Yang S, Xu Y, Zha Y, Ji Y. Tega-Assembler 2: Software Pipeline for Retrieval and Processing of TCGA/CPTAC Data. Bioinf (Oxford England) (2018) 34(9):1615–7. doi: 10.1093/bioinformatics/btx812
21. Gevaert O, Tishbiri R, Plevritis SK. Pancancer Analysis of DNA Methylation-Driven Genes Using MethyMix. Genome Biol (2015) 16:17. doi: 10.1186/s13059-014-0579-8
22. Qu L, Wang ZL, Chen Q, Li YM, He HW, Hisieh JJ, et al. Prognostic Value of a Long non-Coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol (2018) 74(6):756–63. doi: 10.1016/j.eururo.2018.07.032
23. Ren S, Huang S, Ye J, Qian X. Safe Feature Screening for Generalized Lasso. IEEE Trans Pattern Anal Mach Intell (2017) 40(12):2992–3006. doi: 10.1109/TPAMI.2017.277627
24. Fennell L, Dumenil T, Wockner L, Hartel G, Nones K, Bond C, et al. Integrative Genome-Scale Dna Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas. Cell Mol Gastroenterol Hepatol (2019) 8(2):269–90. doi: 10.1016/j.cmg.2019.04.002
25. Williams CS, Bernard JK, Demory Beckler M, Almahayzi D, Washington MK, Smith JJ, et al. Erbb4 is Over-Expressed in Human Colon Cancer and Enhances Cellular Transformation. Carcinogenesis (2015) 36(7):710–8. doi: 10.1093/carcin/bgv049
26. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, et al. Smad4-Mediated Signaling Inhibits Intestinal Neoplasia by Inhibiting Expression of Beta-Catenin. Gastroenterology (2012) 142(3):562–71.e2. doi: 10.1053/j.gastro.2011.11.026
27. Cherradi S, Martineau P, Gongora C, Del Rio M. Claudin Gene Expression Enhances Cellular Transformation. Cancer Res (2015) 75(21):6578–89. doi: 10.1158/0008-5472.CAN-15-1083
28. Huang et al. Model Predicts CRC Prognosis

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.629860/full#supplementary-material
29. Zhang S, Wu Z, Xie J, Yang Y, Wang L, Qiu H. DNA Methylation Exploration for ARDS: A Multi-Omics and Multi-Microarray Interrelated Analysis. *J Exp Med* (2019) 17(1):345. doi: 10.1084/jem.20181277

30. VanderWeele TJ. Explanation in Causal Inference: Developments in Mediation and Interaction. *Int J Epidemiol* (2016) 45(6):1904–8. doi: 10.1093/ije/dyw277

31. Koch A, Joosten SC, Feng Z, de Ruiter TC, Draht MX, Melotte V, et al. Analysis of DNA Methylation in Cancer: Location Visited. *Nat Rev Clin Oncol* (2015) 15(7):459–66. doi: 10.1038/s13571-015-0004-4

32. Liu Y, Liu Y, Huang R, Song W, Wang J, Xiao Z, et al. Dependency of the Cancer-Specific Transcriptional Regulation Circuitry on the Promoter DNA Methylation. *Cell Rep* (2019) 26(12):3461–74.e5. doi: 10.1016/j.celrep.2019.02.084

33. Draht MXG, Goudkade D, Koch A, Grabshi HH, Weijenberg MP, van Engeland M, et al. Prognostic DNA Methylation Markers for Sporadic Colorectal Cancer: A Systematic Review. *Clin Epigenet* (2018) 10:35. doi: 10.1186/s13148-018-0461-8

34. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-Gene Stemness Score for Rapid Determination of Risk in Acute Leukaemia. *Nature* (2016) 540(7633):433–7. doi: 10.1038/nature20598

35. Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, et al. Th9 Cell Development Requires a BATF-Regulated Transcriptional Network. *J Clin Invest* (2013) 123(11):4641–53. doi: 10.1172/JCI69489

36. Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, et al. The AP-1-BATF and -BATF3 Module is Essential for Growth, Survival and TH17/ILC3 Skewing of Anaplastic Large Cell Lymphoma. *Leukemia* (2018) 32(9):1994–2007. doi: 10.1038/s41375-018-0045-9

37. Gil M, Pak HK, Park SJ, Lee AN, Park YS, Lee H, et al. Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226. *Immune Network* (2015) 15(5):260–7. doi: 10.4110/in.2015.15.5.260

38. Feng Y, Pan L, Zhang B, Huang H, Ma H. Batf Acts as an Oncogene in Non-Small Cell Lung Cancer. *Oncol Lett* (2020) 19(1):205–10. doi: 10.3892/ol.2019.11075

39. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, et al. Transcriptional Analysis of HIV-Specific Cdx8+ T Cells Shows That PD-1 Inhibits T Cell Function by Upregulating Batf. *Nat Med* (2010) 16(10):1147–51. doi: 10.1038/nm.2232

40. Yang R, Cheng S, Luo N, Gao R, Yu K, Kang B, et al. Distinct Epigenetic Features of Tumor-Reactive Cdx8+ T Cells in Colorectal Cancer Patients Revealed by Genome-Wide DNA Methylation Analysis. *Genome Biol* (2019) 21(1):2. doi: 10.1186/s13059-019-1921-y

41. Tsai HK, Lehrer J, Alshalahfa M, Erho N, Davicconi E, Lotan TL. Gene Expression Signatures of Neuroendocrine Prostate Cancer and Primary Small Cell Prostatic Carcinoma. *BMC Cancer* (2017) 17(1):759. doi: 10.1186/s12885-017-3279-z

42. Fu H, Ge B, Chen D, Wu Y, Luo Q, Li X, et al. Phytanoyl-CoA 2-Hydroxylase-Interacting Protein-Like Gene is a Therapeutic Target Gene for Glioblastoma Multiforme. *Med Sci Monit: Int Med J Exp Clin Res* (2019) 25:2583–90. doi: 10.12659/MSM.913895

43. Hidalgo A, Baudiz M, Petersen I, Arreola H, Pina P, Vasquez-Ortiz G, et al. Microarray Comparative Genomic Hybridization Detection of Chromosomal Imbalances in Uterine Cervix Carcinoma. *BMC Cancer* (2005) 5:77. doi: 10.1186/1471-2407-5-77

44. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, et al. Hypermethylation-Associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. *Cancer Res* (2002) 62(20):5902–5. doi: 10.1158/0008-5472/2002/25523-X

45. Kuppumbatti YS, Bliewiss JJ, Mandelli JP, Waxman S, Mira YLR. Cellular Retinol-Binding Protein Expression and Breast Cancer. *J Natl Cancer Inst* (2000) 92(6):475–80. doi: 10.1093/jnci/92.6.475

46. Doldo E, Costanza G, Ferlosio A, Pompeo E, Agostinelli S, Bellezza G, et al. High Expression of Cellular Retinol Binding Protein-1 in Lung Adenocarcinoma is Associated With Poor Prognosis. *Genes Cancer* (2015) 6 (11-12):490–502. doi: 10.18632/genesandcancer.89

47. Chen Y, Tian T, Mao MJ, Deng WY, Li H. Crbp-1 Over-Expression is Associated With Poor Prognosis in Tongue Squamous Cell Carcinoma. *BMC Cancer* (2018) 18(1):514. doi: 10.1186/s12885-018-4249-1

48. Mendoza-Rodriguez M, Arreola H, Valdivia A, Peralta R, Serna H, Villegas V, et al. Cellular Retinol Binding Protein 1 Could be a Tumor Suppressor Gene in Cervical Cancer. *Int J Clin Exp Pathol* (2013) 6(9):1817–25. doi: 10.1186/ijep.2013.07.084

49. He D, Zhang YW, Zhang NN, Zhou L, Chen JN, Jiang Y, et al. aberrant Gene Promoter Methylation of P16, Fhit, CRBP1, WWOX, and DCLC-1 in Epstein-Barr Virus-Associated Gastric Carcinomas. *Med Oncol (Northwood London England)* (2019) 32(4):92. doi: 10.1007/s12323-015-0525-y

50. Hermansson M, Hanninen S, Hokynar K, Somerharju P. The PNPLA-Family Phospholipases Involved in Glycophospholipid Homeostasis of Hela Cells. *Biochim Biophys Acta* (2016) 1861(9 Pt A):1058–65. doi: 10.1016/j.bbalip.2016.06.007

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Huang, Fu, Zhang, Xu, Li, Onwuka, Zhang, Zhao, Sun, Zhu, Zheng, Jia, Cui and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.